Geneticists solve a beta blocker puzzle
It was a medical enigma: Why do many black patients respond differently to a class of heart drugs called beta blockers? Researchers now say a genetic variant allows 40 percent of black patients to produce their own version of the drugs. Dr. Stephen Liggett tells The Takeaway about his study and the potential impacts on health care.
Guest: Dr. Stephen Liggett, director of Cardiopulmonary Genomics at University of Maryland Medical Center.
The World is an independent newsroom. We’re not funded by billionaires; instead, we rely on readers and listeners like you. As a listener, you’re a crucial part of our team and our global community. Your support is vital to running our nonprofit newsroom, and we can’t do this work without you. Will you support The World with a gift today? Donations made between now and Dec. 31 will be matched 1:1. Thanks for investing in our work!